Mavrilimumab
Mavrilimumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | GM-CSF receptor alpha chain |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| IUPHAR/BPS |
|
| ChemSpider |
|
| UNII |
|
| Chemical and physical data | |
| Formula | C6706H10438N1762O2104S54 |
| Molar mass | 143.2 kg/mol |
 N Y (what is this?) (verify) | |
Mavrilimumab is a human monoclonal antibody[1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).[2]
Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc.[3] as an investigational drug for the treatment of rheumatoid arthritis
Mavrilimumab has been studied in a phase 1 dose-ranging trial[2] and a phase 2a clinical trial, both sponsored by Medimmune.[4] The phase 2a trial, which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).[4]
As of 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.[5]
In early 2017 the phase IIb study was reported to be showing promising results.[6]
References[edit]
^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ ab Gerd R Burmester; Eugen Feist; Matthew A Sleeman; Bing Wang; Barbara White; Fabio Magrini (1 September 2011). "Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study". Ann. Rheum. Dis. 70 (9): 1542–1549. doi:10.1136/ard.2010.146225. PMC 3147227. PMID 21613310.
^ "Archived copy" (PDF). Archived from the original (PDF) on 2012-09-28. Retrieved 2011-09-08.CS1 maint: Archived copy as title (link)
^ ab Gerd R Burmester; Michael E Weinblatt; Iain B McInnes; Duncan Porter; Olga Barbarash; Mykola Vatutin; Istvan Szombati; Ehsanollah Esfandiari; Matthew A Sleeman; Christopher D Kane; Guy Cavet; Bing Wang; Alex Godwood; Fabio Magrini & the EARTH Study Group (2013). "Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis". Ann Rheum Dis. 72 (9): 1445–1452. doi:10.1136/annrheumdis-2012-202450. PMC 3756523. PMID 23234647.
^ Manuela Di Franco; Maria Chiara Gerardi; Bruno Lucchino & Fabrizio Conti (12 March 2014). "Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis". Core Evidence. 9: 41–48. doi:10.2147/CE.S39770. PMC 3958547. PMID 24648832.
^ Agent that Targets GM-CSF Shows Promise in RA - Novel monoclonal antibody was rapidly effective in mild-to-moderate disease. Feb 2017
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.760","walltime":"1.189","ppvisitednodes":"value":4346,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":137033,"limit":2097152,"templateargumentsize":"value":2411,"limit":2097152,"expansiondepth":"value":16,"limit":40,"expensivefunctioncount":"value":3,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":17056,"limit":5000000,"entityaccesscount":"value":3,"limit":400,"timingprofile":["100.00% 999.713 1 -total"," 64.55% 645.306 1 Template:Drugbox"," 39.50% 394.842 1 Template:Infobox"," 11.60% 115.990 2 Template:Cite_web"," 10.78% 107.808 16 Template:Unbulleted_list"," 9.94% 99.419 3 Template:Cite_journal"," 9.82% 98.222 9 Template:Navbox"," 7.79% 77.886 1 Template:Infobox_drug/chemical_formula"," 5.62% 56.155 1 Template:Monoclonals_for_immune_system"," 3.73% 37.315 1 Template:Chem_molar_mass"],"scribunto":"limitreport-timeusage":"value":"0.304","limit":"10.000","limitreport-memusage":"value":4623535,"limit":52428800,"cachereport":"origin":"mw1253","timestamp":"20181010151758","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":69,"wgHostname":"mw1333"););
Clash Royale CLAN TAG